-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The positive clinical data of Merck's oral antiviral drug molnupiravir in the treatment of COVID-19 is continuing to bring great returns to the company
.
This Wednesday, only one day after announcing that it had signed a $1 billion sales order with the US government, the company disclosed another major supply transaction
The Japanese government has agreed to pay US$1.
2 billion to Merck and its partner Ridgeback Therapeutics for 1.
6 million courses of molnupiravir, or US$750 per course
.
The transaction depends on whether molnupiravir can be authorized or approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan
Merck said the day before that the U.
S.
government has agreed to purchase another 1.
4 million courses of molnupiravir at a price of $1 billion
.
Coupled with an earlier purchase, this new order brings the total purchase of molnupiravir by the US government to 3.
In early October, Merck and Ridgeback Therapeutics announced the positive results of the Phase 3 MOVe-OUT clinical trial
.
The trial was carried out in non-hospitalized adult patients (age ≥18 years) confirmed by laboratory testing as mild to moderate COVID-19.
According to the above data, molnupiravir was approved by the UK regulatory agency last week, which also represents the first global regulatory approval for molnupiravir
.
The British government has reached a procurement agreement with Merck to purchase 480,000 courses of molnupiravir
Merck said that even before the release of positive phase 3 clinical data, the company has been building molnupiravir supply chain capabilities
.
Merck expects to be able to provide 10 million treatment courses by the end of 2021 and 20 million treatment courses by 2022
At the same time, molnupiravir is about to usher in competitors
.
Last week, Pfizer reported that in a Phase 2/3 clinical trial, its oral antiviral drug paxlovid (every 12 hours, treatment for 5 days) hospitalized or The risk of death was reduced by 89%
Original English: https://
https://
